1013 results about "Long chain fatty acid" patented technology

The present invention comprises methods and compositions for antimicrobial silver compositions comprising silver nanoparticles. The present invention further comprises compositions for preparing silver nanoparticles comprising at least one stabilizing agent, one or more silver compounds, at least one reducing agent and a solvent. In one aspect, the stabilizing agent comprises a surfactant or a polymer. The polymer may comprise polymers such as polyacrylamides, polyurethanes, and polyamides. In one aspect, the silver compound comprises a salt comprising a silver cation and an anion. The anion may comprise saccharinate derivatives, long chain fatty acids, and alkyl dicarboxylates. The methods of the present invention comprise treating devices with the silver nanoparticle compositions, including, but not limited to, such devices as woven wound care materials, catheters, patient care devices, and collagen matrices. The present invention further comprises treatment of humans and animals wacr6ith the antimicrobial devices described herein.

The present invention comprises methods and compositions comprising metal nanoparticles. The invention comprises metal nanoparticles and surfaces treated with a metal nanoparticle coating. The present invention further comprises compositions for preparing nanoparticles comprising at least one stabilizing agent, one or more metal compounds, at least one reducing agent and a solvent. In one aspect, the stabilizing agent comprises a surfactant or a polymer. The polymer may comprise polymers such as polyacrylamides, polyurethanes, and polyamides. In one aspect, the metal compound comprises a salt comprising a metal cation and an anion. The anion may comprise saccharinate derivatives, long chain fatty acids, and alkyl dicarboxylates.

The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.

The present invention comprises methods and compositions for antimicrobial devices comprising metal containing compositions which are resistant to heat and light discoloration. The metal containing compositions may comprise salts or complexes of silver, copper or zinc. In one aspect the compositions comprise silver salts. In another aspect, the compositions comprise silver complexes. In one aspect, the metal salts may comprise metal salts of saccharin, acesulfame, long chain fatty acids, and alkyl dicarboxylic acids. The compositions further comprise polymers which form salts or complexes with silver, copper or zinc. The methods of the present invention comprise treating devices with the metal containing compositions, including, but not limited to, such devices as woven wound care materials, catheters, patient care devices, and collagen matrices. The present invention further comprises treatment of humans and animals with the antimicrobial devices described herein.

A skin barrier lotion for protection against contact with irritants comprises: about 5 to 15 percent by weight of a long-chain fatty acid; about 1 to 5 percent by weight of a long-chain fatty alcohol; about 1 to 10 percent by weight of a hydrocarbon oil; about 1 to 30 percent by weight of a silicone skin protectant; about 0.5 to about 5 percent by weight of an alkanolamine; about 0.5 to about 5 percent by weight of a humectant; about 0.5 to about 10 percent by weight of an inorganic skin protectant; about 0.5 to 15 weight percent of a preservative; and about 50 to 90 percent by weight water. Optionally, the lotion will also contain up to about 5 percent by weight of a fragrance, odor neutralizer or a mixture thereof.

A method for preparing electro-optical polymer-liquid crystal photonic crystals, comprising: disposing between at least two optically transparent electrode plates, a polymer-dispersed liquid crystal material that comprises, before exposure:(a) a polymerizable monomer comprising at least one acrylate;(b) a liquid crystal;(c) a chain-extending monomer;(d) a coinitiator;(e) a photoinitiator; and(f) a long chain aliphatic acid;and exposing this polymer-dispersed liquid crystal material to light in an interference pattern.

Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.

Cleaning compositions comprising (A) N-long-chain acyl neutral amino acid or a salt thereof, (B) N-long-chain acyl neutral amino acid dipeptide or a salt thereof, and (C) N-long-chain acyl neutral amino acid tripeptide or a salt thereof provide abundant foam, are excellent in foam retaining properties, and furnish a cleaned and dried body or hair with both a smooth feeling and a moist feeling. Compositions which further comprise (D) a higher fatty acid having 8 to 22 carbon atoms or a salt thereof exhibit enhanced creamy properties in foam quality. N-long-chain acyl neutral amino acids or salts thereof may be conveniently prepared by mixing a neutral amino acid, a long-chain fatty acid, and at least one of an alkaline substance selected from sodium hydroxide and potassium hydroxide, and maintaining the mixture with heating, while removing the water produced during the reaction, with no catalyst being employed.

The invention discloses an application of a long-chain fatty acid derivative shown as formula 5 or plant extracts containing the same in preparing preparations to inhibit the activity of aromatizing enzyme and in preparing pharmaceutical compositions to prevent or treat prostatoplasia diseases. The application opens up a new application field for the compound and also provides a new way for preventing and treating the diseases in the field.

This invention relates to a solid oral dosage form containing one or more pharmaceutically active ingredients solubilised or suspended in a pharmaceutically acceptable solvent or liquid phase and encapsulated in seamless controlled release microcapsules. Accordingly the pharmaceutically acceptable solvent or liquid phase may range from aqueous phase, organic solvent(s), glycols, oils and derivatives of including mono-,di, and triglycerides of short, medium and long chain fatty acids. The microcapsules have a diameter of <1 mm to 8 mm and a drug loading of up to 90%. Additionally the microcapsules may be coated to release the pharmaceutically active ingredient at specific sites and for predetermined rates.

The invention relates to a low-odour polypropylene compound, the compound comprises (by weight ratio) polypropylene 55-95, talcum powder 0-40, fatty acid ester compound 0.5-3, nano zinc oxide 0.5-3, nano titanium oxide 0.5-3, heat stabilizer DSTP 0.1-1.0, heat stabilizer 3114 0.1-1.0, heat stabilizer 618 0.1-0.5, wherein the fatty acid ester compound being C25-C45 long-chain fatty acid ester, the heat stabilizer DSTP being octadecyl thiodipropionate, the heat stabilizer 3114 being 3,obtaining 5-ditert-butyl-4-hydroxy benzylphosphonate diethylate, the heat stabilizer being dioctadecyl pentaerythritol diphosphite.

Thickened, preferably thixotropic oil compositions are disclosed comprised of high proportions of edible oils, in particular unsaturated oils, and edible solidifying agents, in particular long chain fatty acids and / or long chain fatty alcohols, for use in the preparation of edible foods and medicinal / therapeutic products. Further disclosed are methods for the production of the thickened, thixotropic oil compositions, edible food and medicinal / therapeutic products containing same and methods of their production and consumption.

The present invention discloses a water-based cutting fluid for vermicular cast iron processing, and a dilution solution thereof. The water based cutting fluid comprises 3-10% of an anti-rust additive, 4-10% of fatty acid amide, 2-3% of organic amine, 3-10% of long-chain fatty acid, 2-5% of fatty alcohol polyoxyethylene ether, 5-8% of petroleum sodium sulfonate, 1-5% of a coupling agent, 10-15% of an extreme pressure additive, 15-20% of a synthetic ester, 1-2% of a sterilization agent, 0.5-1.0% of an anti-forming agent, and 32-45% of water, wherein the anti-rust additive is a boric acid anti-rust additive and dicarboxylic acid, and the coupling agent is a fatty alcohol and / or aliphatic ether. The water-based cutting fluid of the present invention has characteristics of good lubrication performance, good cooling performance, good anti-rust property, no chlorine, diamine, nitrite and other nitro compounds, no environmental pollution, no irritating odor, easy cutting, easy powder settlement, and effective cutter service life prolonging.

A personal care product composition containing a long chain fatty acid cellulose ester (LCCE) having a degree of substitution greater than about 1.0 of an ester substituent or residue from fatty acids having from 6 to 18 carbon atoms wherein the LCCE is soluble in at least one cosmetically acceptable solvent selected from the group consisting of hydrocarbons, alkyl esters, fats and oils, fatty acids, fatty alcohols, and silicone oils.

The invention is a cosmetic or dermatological preparation comprising taurine and at least one substance selected from the group consisting of phytosterols, ceramides, long-chain fatty acids, and cholesterol. The invention also includes a method of strengthening the skin barrier comprising applying to the skin a preparation comprising taurine and at least one substance selected from the group consisting of phytosterols, ceramides, long-chain fatty acids, and cholesterol. The invention also includes methods of moisturizing the skin, improving the microtopography of the skin, improving the elasticity of the skin, treating or preventing functional disorders of skin appendages, treating or preventing the symptoms of skin ageing, and treating or preventing the harmful effects of ultraviolet radiation on the skin comprising applying the preparation.

An animal feed with a high level of arachidonic acid is produced from microalgae, and fed to aquatic animals grown in aquaculture. The arachidonic acid-rich microalgae are fed directly to the aquatic animals, or processed to produce an oil that can be used as a human nutritive supplement. The arachidonic acid-rich microalgae can be combined with long chain omega-3 fatty acids to provide a source of nutrition for humans and animals. The animal feed and nutritional supplements are free of animal byproducts.

Aspects of the invention relate to beverage compositions, including, for example, concentrated and ready-to-drink formulations sweetened with at least one non-nutritive sweetener and further including a long chain fatty acid compound in an amount sufficient to reduce the off-note taste of the non-nutritive sweetener. In certain embodiments, the long chain fatty acid may be one or more of the following: lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, alpha-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, erucic acid, adipic acid, and palmitic acid. In certain exemplary embodiments, a plurality of different long chain fatty acids are utilized. In another embodiments, the long chain fatty acids comprise both natural and synthetic fatty acids.

An animal feed supplement includes fish meal as a source of omega 3 long chain fatty acids for inclusion in the diet of an animal. The animal feed supplement also includes at least one naturally-occurring antioxidant; at least one synthetic antioxidant; an antibacterial agent; an anti-mold / anti-fungal agent; and an anti-chemical activity agent. The omega 3 long chain fatty acids are provided at a level which maximises the nutritional value of food produce from the animal, but without taint of the food produce. The feed supplement is greater than 5% of the total dietary intake of the animal.

The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially live of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for hyperhidrosis with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.

The invention provides a method for preparing alkane fuel with a high cetane number by catalyzing plant oil or long-chain fatty acid by a Ru catalyst, which comprises the following steps: (1) mixing plant oil or long-chain fatty acid with a solvent in proportion; (2) adding a catalyst with the hydrogenation function into the mixed solution in step (1); (3) reacting in reducing atmosphere to obtain long-chain alkane with a main component of C15-C18. The method for catalyzing plant oil or long-chain fatty acid by a Ru catalyst provided by the invention has a high fatty acid conversion rate and a high alkane yield. In addition, the method of the invention is simple in process, convenient for operation, and mild in reaction condition; the whole reaction process is basically free of carbon deposition; the catalyst is cheap, easily available, and suitable for multi-time repeated use without activity reduction. The product of the invention can be used directly as diesel oil, and has important economic and social meaning for vehicle liquid fuel sustainable supply.

The invention provides a plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically beneficial substances to a plant, and for enhancing the translocation of such delivered substance(s) in or on the plant, the formulation comprising a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous carrier, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. The dispersion is preferably characterized in that at least 50% of the vesicles or microsponges are of a diametrical size of between 50 nm and 5 micrometers. The dispersion is further also characterized in that the micro-emulsion has a zeta potential of between −25 mV and −60 mV

This invention is related to the obtention of a new natural mixture composed of long chain fatty alcohols and long chain fatty acids. This mixture has a relative composition of long chain fatty alcohols and long chain fatty acids that is highly reproducible batch to batch and it is extracted from animal or vegetable wax. This mixture has specific therapeutic properties that support its use as an active component of dietary supplement formulations for reducing serum cholesterol levels (while not decreasing HDL-cholesterol levels) and therefore is effective treating Hypercholesterolemia and reducing the risk of coronary heart disease. This mixture also has been shown to improve male sexual activity. When used in conjunction with salicylic acid the mixture has other therapeutic effects such as inhibiting the atherosclerotic process, platelet hyperaggregability, inhibiting thrombosis and inhibiting inflammation.

Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and / or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.

The invention discloses a high-performance thermosetting epoxy asphalt binder, comprising a part A component and a part B compound, wherein the part A component comprises 100 weight parts of epoxy resin, 20-35 weight parts of flexibilizer, 0.5-2 weight parts of promoter, and 8-20 weight parts of diluent; the part B component comprises 300-350 weight parts of asphalt, 150-160 weight parts of flexible curing agent, 10-15 weight parts of promoter, 2-5 weight parts of compatilizer, and 100 weight parts of diluent; and the ratio of the part A component to the part B component is 100:350-440. According to the invention, by using flexible long-chain fatty acid anhydride as the curing agent and carrying out solidification reaction on the curing agent with the epoxy resin, a stereo cross-linked structure is formed, and the bonding capability and water resistance of asphalt are increased; by using liquid rubber as the flexibilizer, the flexibility of the epoxy asphalt binder is raised to adapt to the flexibility of a steel plate, and by prereacting the flexibilizer with epoxy resin firstly for grafting, the compatibility between the epoxy asphalt binder and asphalt is raised. The epoxy asphalt binder is suitable for bonding and waterproofing of steel bridge floor, cement concrete bridge floor, tunnel, highway and other pavements. The invention also discloses a preparation method of the epoxy asphalt binder.

A controlled release composition for a biologically active material, which composition is liquid or liquid crystalline and comprises at least one medium or long-chain fatty acid ester of diglycerol as a carrier for said biologically active material, said biologically active material being dissolved or dispersed in said carrier. Said composition is especially useful as a medical composition.

The present invention comprises methods and compositions comprising metal nanoparticles. The invention comprises metal nanoparticles and surfaces treated with a metal nanoparticle coating. The present invention further comprises compositions for preparing nanoparticles comprising at least one stabilizing agent, one or more metal compounds, at least one reducing agent and a solvent. In one aspect, the stabilizing agent comprises a surfactant or a polymer. The polymer may comprise polymers such as polyacrylamides, polyurethanes, and polyamides. In one aspect, the metal compound comprises a salt comprising a metal cation and an anion. The anion may comprise saccharinate derivatives, long chain fatty acids, and alkyl dicarboxylates.

The invention relates to a magnetic cation exchange resin catalyzer and a preparation method and application thereof. In the method, nanometer magnetic metal oxide and long-chain fatty acid are mixed in the water the pH of which is 9-12, the pH is regulated to 4-5, and modified nanometer magnetic particulate is obtained after the nanometer magnetic metal oxide and the long-chain fatty acid react; monomer, evocating agents, crosslinking agents and pore-foaming agents are mixed with the modified nanometer magnetic particulate which accounts for 5-65% of the total weight of the monomer and the crosslinking agents, magnetic resin is obtained after polymerization, and the catalyzer is obtained through sulphur reaction of the magnetic resin. The catalyzer can be used for catalyzing olefin hydration reaction, ether hydrolysis reaction, esterification reaction, etherealization reaction, condensation reaction or aromatic hydrocarbon alkylation reaction in a magnetic reactor.